Identification of manipulated variables for a glycosylation control strategy

Biotechnology and Bioengineering

Volumn 111, Issue 10, 2014, Pages 1957-1970

  St Amand, Melissa M ^a   Radhakrishnan, Devesh ^a   Robinson, Anne S ^a,b   Ogunnaike, Babatunde A ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b Tulane University   (United States)

Author keywords

Controllability; Design of experiments (DoE); Enzyme expression; Glycosylation; Media supplements; Monoclonal antibody; Nucleotide sugar

Indexed keywords

CONTROLLABILITY; DESIGN OF EXPERIMENTS; ENZYMES; ESTERIFICATION; GLYCOSYLATION; MONOCLONAL ANTIBODIES; NUCLEOTIDES; PROTEINS;

BIOPHARMACEUTICAL MANUFACTURERS; CULTURE CONDITIONS; GLYCOSYLATION CONTROLS; MANIPULATED VARIABLES; MEDIA SUPPLEMENTS; NUCLEOTIDE SUGAR; RELATIVE ABUNDANCE; THERAPEUTIC PROTEIN;

POLYSACCHARIDES;

AMMONIA; GALACTOSE; GLUTAMIC ACID; GLYCAN; MANGANESE; NITROGEN; SUGAR NUCLEOTIDE; CULTURE MEDIUM; IMMUNOGLOBULIN G; POLYSACCHARIDE;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CULTURE; CELL METABOLISM; CELL VIABILITY; CONTROL STRATEGY; CONTROLLED STUDY; ENZYME GLYCOSYLATION; FEMALE; GOLGI COMPLEX; MOLECULAR INTERACTION; NONHUMAN; OSMOLALITY; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BIOREACTOR; BIOTECHNOLOGY; CHEMISTRY; CHO CELL LINE; CRICETULUS; CULTURE MEDIUM; CULTURE TECHNIQUE; GENE EXPRESSION REGULATION; GLYCOSYLATION; HAMSTER; METABOLISM; PROCEDURES;

AMMONIA; ANIMALS; BIOREACTORS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CHO CELLS; CRICETINAE; CRICETULUS; CULTURE MEDIA; GALACTOSE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOSYLATION; IMMUNOGLOBULIN G; MANGANESE; POLYSACCHARIDES;

EID: 84904365784     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25251     Document Type: Article

References (28)

1. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc. Science 320(5874):373-376.
2. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21-50.
3. Chen PF, Harcum SW. 2005. Effects of amino acid additions on ammonium stressed CHO cells. J Biotechnol 117(3):277-286.
4. Chen PF, Harcum SW. 2006. Effects of elevated ammonium on glycosylation gene expression in CHO cells. Metab Eng 8(2):123-132.
5. Federici M, Lubiniecki A, Manikwar P, Volkin DB. 2013. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals 41(3):131-147.
6. Gawlitzek M, Estacio M, Furch T, Kiss R. 2009. Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells. Biotechnol Bioeng 103(6):1164-1175.
7. Gawlitzek M, Ryll T, Lofgren J, Sliwkowski MB. 2000. Ammonium alters N-glycan structures of recombinant TNFR-IgG: Degradative versus biosynthetic mechanisms. Biotechnol Bioeng 68(6):637-646.
8. Grainger RK, James DC. 2013. CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation. Biotechnol Bioeng 110(11):2970-2983.
9. Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer ETJ, Gerritsen J, van Berkel PHC. 2011. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng 108(7):1591-1602.
10. Harvey DJ, Merry AH, Royle L, Campbell MP, Dwek RA, Rudd PM. 2009. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 9(15):3796-3801.
11. Hills AE, Patel AK, Boyd PN, James DC. 2000. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Glycobiology 10(10):1108-1108.
12. Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21(6):1644-1652.
13. Hong JK, Cho SM, Yoon SK. 2010. Substitution of glutamine by glutamate enhances production and galactosylation of recombinant IgG in Chinese hamster ovary cells. Appl Microbiol Biotechnol 88(4):869-876.
14. Jones AJS, Papac DI, Chin EH, Keck R, Baughman SA, Lin YS, Kneer J, Battersby JE. 2007. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17(5):529-540.
15. Kaneko Y, Nimmerjahn F, Ravetch EV. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787):670-673.
16. Kochanowski N, Blanchard F, Cacan R, Chirat F, Guedon E, Marc A, Goergen JL. 2006. Intracellular nucleotide and nucleotide sugar contents of cultured CHO cells determined by a fast, sensitive, and high-resolution ion-pair RP-HPLC. Anal Biochem 348(2):243-251.
17. Konno Y, Kobayashi Y, Takahashi K, Takahashi E, Sakae S, Wakitani M, Yamano K, Suzawa T, Yano K, Ohta T, Koike M, Wakamatsu K, Hosoi S. 2012. Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity. Cytotechnology 64(3):249-265.
18. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25(4):402-408.
19. McCamish M, Woollett G. 2013. The continuum of comparability extends to biosimilarity: How much is enough and what clinical data are necessary? Clin Pharmacol Ther 93(4):315-317.
20. Pacis E, Yu M, Autsen J, Bayer R, Li F. 2011. Effects of cell culture conditions on antibody N-linked Glycosylation-what affects high mannose 5 glycoform. Biotechnol Bioeng 108(10):2348-2358.
21. Raju TS. 2008. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20(4):471-478.
22. Scallon BJ, Tam SH, McCarthy SG, Cal AN, Raju TS. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44(7):1524-1534.
23. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. 2011. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29(4):310-312.
24. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277(30):26733-26740.
25. St. Amand MM, Tran K, Radhakrishnan D, Robinson AS, Ogunnaike BA. 2014. Controllability analysis of protein glycosylation in Cho cells. PLoS ONE 9(2):e87973. doi: 10.1371/journal.pone.0087973
26. Witsell DL, Casey CE, Neville MC. 1990. Divalent-cation activation of galactosyltransferase in native mammary golgi vesicles. J Biol Chem 265(26):15731-15737.
27. Wong DCF, Wong KTK, Goh LT, Heng CK, Yap MGS. 2005. Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol Bioeng 89(2):164-177.
28. Wright A, Sato Y, Okada T, Chang KH, Endo T, Morrison SL. 2000. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10(12):1347-1355.